Skip to main content
Top
Published in: AIDS Research and Therapy 1/2024

Open Access 01-12-2024 | Human Immunodeficiency Virus | Research

The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants

Authors: Sara Bohnstedt Mørup, Preston Leung, Cavan Reilly, Brad T. Sherman, Weizhong Chang, Maja Milojevic, Ana Milinkovic, Angelike Liappis, Line Borgwardt, Kathy Petoumenos, Roger Paredes, Shweta S. Mistry, Cameron R. MacPherson, Jens Lundgren, Marie Helleberg, Joanne Reekie, Daniel D. Murray, for the INSIGHT FIRST and START study groups

Published in: AIDS Research and Therapy | Issue 1/2024

Login to get access

Abstract

Background

Human genetic contribution to HIV progression remains inadequately explained. The type 1 interferon (IFN) pathway is important for host control of HIV and variation in type 1 IFN genes may contribute to disease progression. This study assessed the impact of variations at the gene and pathway level of type 1 IFN on HIV-1 viral load (VL).

Methods

Two cohorts of antiretroviral (ART) naïve participants living with HIV (PLWH) with either early (START) or advanced infection (FIRST) were analysed separately. Type 1 IFN genes (n = 17) and receptor subunits (IFNAR1, IFNAR2) were examined for both cumulated type 1 IFN pathway analysis and individual gene analysis. SKAT-O was applied to detect associations between the genotype and HIV-1 study entry viral load (log10 transformed) as a proxy for set point VL; P-values were corrected using Bonferroni (P < 0.0025).

Results

The analyses among those with early infection included 2429 individuals from five continents. The median study entry HIV VL was 14,623 (IQR 3460–45100) copies/mL. Across 673 SNPs within 19 type 1 IFN genes, no significant association with study entry VL was detected. Conversely, examining individual genes in START showed a borderline significant association between IFNW1, and study entry VL (P = 0.0025). This significance remained after separate adjustments for age, CD4+ T-cell count, CD4+/CD8+ T-cell ratio and recent infection. When controlling for population structure using linear mixed effects models (LME), in addition to principal components used in the main model, this was no longer significant (p = 0.0244). In subgroup analyses stratified by geographical region, the association between IFNW1 and study entry VL was only observed among African participants, although, the association was not significant when controlling for population structure using LME. Of the 17 SNPs within the IFNW1 region, only rs79876898 (A > G) was associated with study entry VL (p = 0.0020, beta = 0.32; G associated with higher study entry VL than A) in single SNP association analyses. The findings were not reproduced in FIRST participants.

Conclusion

Across 19 type 1 IFN genes, only IFNW1 was associated with HIV-1 study entry VL in a cohort of ART-naïve individuals in early stages of their infection, however, this was no longer significant in sensitivity analyses that controlled for population structures using LME.
Appendix
Available only for authorised users
Literature
2.
go back to reference Fraser C, Lythgoe K, Leventhal GE, Shirreff G, Hollingsworth TD, Alizon S, et al. Virulence and pathogenesis of HIV-1 infection: An evolutionary perspective. Science. 2014;343(6177):1–18.CrossRef Fraser C, Lythgoe K, Leventhal GE, Shirreff G, Hollingsworth TD, Alizon S, et al. Virulence and pathogenesis of HIV-1 infection: An evolutionary perspective. Science. 2014;343(6177):1–18.CrossRef
4.
go back to reference Gabrielaite M, Bennedbæk M, Zucco AG, Ekenberg C, Murray DD, Kan VL, et al. Human immunotypes impose selection on viral genotypes through viral epitope specificity. J Infect Dis. 2021;224(12):2053–63.PubMedPubMedCentralCrossRef Gabrielaite M, Bennedbæk M, Zucco AG, Ekenberg C, Murray DD, Kan VL, et al. Human immunotypes impose selection on viral genotypes through viral epitope specificity. J Infect Dis. 2021;224(12):2053–63.PubMedPubMedCentralCrossRef
5.
go back to reference Marmor M, Hertzmark K, Thomas SM, Halkitis PN, Vogler M. Resistance to HIV infection. J Urban Heal. 2006;83(1):5–17.CrossRef Marmor M, Hertzmark K, Thomas SM, Halkitis PN, Vogler M. Resistance to HIV infection. J Urban Heal. 2006;83(1):5–17.CrossRef
6.
go back to reference Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009;5(12):e1000791.PubMedPubMedCentralCrossRef Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009;5(12):e1000791.PubMedPubMedCentralCrossRef
7.
go back to reference McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, et al. Evaluating the impact of functional genetic variation on HIV-1 control. J Infect Dis. 2017;216(9):1063–9.PubMedPubMedCentralCrossRef McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, et al. Evaluating the impact of functional genetic variation on HIV-1 control. J Infect Dis. 2017;216(9):1063–9.PubMedPubMedCentralCrossRef
8.
go back to reference Tough RH, McLaren PJ. Interaction of the host and viral genome and their influence on HIV disease. Front Genet. 2019;10:1–9. Tough RH, McLaren PJ. Interaction of the host and viral genome and their influence on HIV disease. Front Genet. 2019;10:1–9.
9.
go back to reference Ohainle M, Helms L, Vermeire J, Roesch F, Humes D, Basom R, et al. A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife. 2018;7:1–32.CrossRef Ohainle M, Helms L, Vermeire J, Roesch F, Humes D, Basom R, et al. A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife. 2018;7:1–32.CrossRef
10.
go back to reference Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet. 2010;11(12):843–54.PubMedCrossRef Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet. 2010;11(12):843–54.PubMedCrossRef
11.
go back to reference Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591(7848):92–8.PubMedCrossRef Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591(7848):92–8.PubMedCrossRef
12.
go back to reference Al QZ, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:4570.CrossRef Al QZ, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:4570.CrossRef
13.
go back to reference Diop G, Hirtzig T, Do H, Coulonges C, Vasilescu A, Labib T, et al. Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother. 2006;60(9):569–77.PubMedCrossRef Diop G, Hirtzig T, Do H, Coulonges C, Vasilescu A, Labib T, et al. Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother. 2006;60(9):569–77.PubMedCrossRef
14.
go back to reference Sandstrom TS, Ranganath N, Angel JB. Impairment of the type I interferon response by HIV-1: Potential targets for HIV eradication. Cytokine Growth Factor Rev. 2017;2017(37):1–16.CrossRef Sandstrom TS, Ranganath N, Angel JB. Impairment of the type I interferon response by HIV-1: Potential targets for HIV eradication. Cytokine Growth Factor Rev. 2017;2017(37):1–16.CrossRef
18.
go back to reference Yin X, Langer S, Zhang Z, Herbert KM, Yoh S. Sensor sensibility—HIV-1 and the innate immune response. Cells. 2019;9:1–18. Yin X, Langer S, Zhang Z, Herbert KM, Yoh S. Sensor sensibility—HIV-1 and the innate immune response. Cells. 2019;9:1–18.
19.
go back to reference Gingras SN, Tang D, Tuff J, McLaren PJ. Minding the gap in HIV host genetics: opportunities and challenges. Human Genet. 2020;139:865–75.CrossRef Gingras SN, Tang D, Tuff J, McLaren PJ. Minding the gap in HIV host genetics: opportunities and challenges. Human Genet. 2020;139:865–75.CrossRef
20.
go back to reference Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS. 2004;18(12):1697–705.PubMedCrossRef Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS. 2004;18(12):1697–705.PubMedCrossRef
21.
go back to reference Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, et al. Association between single-nucleotide polymorphisms in hla alleles and human immunodeficiency virus type 1 viral load in demographically diverse, antiretroviral therapy-naive participants from the strategic timing of antiretroviral treatment trial. J Infect Dis. 2019;220(8):1325–34.PubMedPubMedCentralCrossRef Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, et al. Association between single-nucleotide polymorphisms in hla alleles and human immunodeficiency virus type 1 viral load in demographically diverse, antiretroviral therapy-naive participants from the strategic timing of antiretroviral treatment trial. J Infect Dis. 2019;220(8):1325–34.PubMedPubMedCentralCrossRef
22.
go back to reference MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 05. Lancet. 2006;368(9553):2125–35.PubMedCrossRef MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 05. Lancet. 2006;368(9553):2125–35.PubMedCrossRef
24.
go back to reference Murray DD, Grund B, Macpherson CR, Ekenberg C, Zucco AG, Reekie J, et al. Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV. AIDS. 2023;37(3):379–87.PubMedCrossRef Murray DD, Grund B, Macpherson CR, Ekenberg C, Zucco AG, Reekie J, et al. Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV. AIDS. 2023;37(3):379–87.PubMedCrossRef
26.
go back to reference Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022;50(D1):D687-92.PubMedCrossRef Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 2022;50(D1):D687-92.PubMedCrossRef
28.
go back to reference Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl. Nucleic Acids Res. 2022;50(D1):988–95.CrossRef Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl. Nucleic Acids Res. 2022;50(D1):988–95.CrossRef
30.
go back to reference Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.PubMedCrossRef Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.PubMedCrossRef
31.
go back to reference Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2013;44(8):955–9.CrossRef Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2013;44(8):955–9.CrossRef
32.
go back to reference Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(1):1–16.CrossRef Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4(1):1–16.CrossRef
33.
go back to reference Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods. 2013;10(1):5–6.PubMedCrossRef Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods. 2013;10(1):5–6.PubMedCrossRef
35.
go back to reference Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904–9.PubMedCrossRef Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904–9.PubMedCrossRef
36.
go back to reference Kao PYP, Leung KH, Chan LWC, Yip SP, Yap MKH. Pathway analysis of complex diseases for GWAS, extending to consider rare variants, multi-omics and interactions. Biochim Biophys Acta Gen Subj. 2017;1861(2):335–53.PubMedCrossRef Kao PYP, Leung KH, Chan LWC, Yip SP, Yap MKH. Pathway analysis of complex diseases for GWAS, extending to consider rare variants, multi-omics and interactions. Biochim Biophys Acta Gen Subj. 2017;1861(2):335–53.PubMedCrossRef
37.
41.
go back to reference Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez gene: gene-centered information at NCBI. Nucl Acids Res. 2007;35(SUPPL. 1):26–31.CrossRef Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez gene: gene-centered information at NCBI. Nucl Acids Res. 2007;35(SUPPL. 1):26–31.CrossRef
42.
45.
go back to reference Schlusser KE, Sharma S, de la Torre P, Tambussi G, Draenert R, Pinto AN, et al. Comparison of self-report to biomarkers of recent hiv infection: findings from the start trial. AIDS Behav. 2018;22(7):2277–83.PubMedPubMedCentralCrossRef Schlusser KE, Sharma S, de la Torre P, Tambussi G, Draenert R, Pinto AN, et al. Comparison of self-report to biomarkers of recent hiv infection: findings from the start trial. AIDS Behav. 2018;22(7):2277–83.PubMedPubMedCentralCrossRef
48.
go back to reference Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucl Acids Res. 2018;46(D1):D1062-7.PubMedCrossRef Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucl Acids Res. 2018;46(D1):D1062-7.PubMedCrossRef
49.
go back to reference Li S, Zhao F, Shao J, Xie Y, Chang H, Zhang Y. Interferon-omega: current status in clinical applications Shi-fang. Int Immunopharmacol. 2017;52:253–60.PubMedPubMedCentralCrossRef Li S, Zhao F, Shao J, Xie Y, Chang H, Zhang Y. Interferon-omega: current status in clinical applications Shi-fang. Int Immunopharmacol. 2017;52:253–60.PubMedPubMedCentralCrossRef
50.
go back to reference Künzi MS, Pitha PM. Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication. J Interf Cytokine Res. 1996;16(11):919–27.CrossRef Künzi MS, Pitha PM. Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication. J Interf Cytokine Res. 1996;16(11):919–27.CrossRef
52.
go back to reference Refae S, Gal J, Ebran N, Otto J, Borchiellini D, Peyrade F, et al. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest New Drugs. 2020;38(1):160–71.PubMedCrossRef Refae S, Gal J, Ebran N, Otto J, Borchiellini D, Peyrade F, et al. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest New Drugs. 2020;38(1):160–71.PubMedCrossRef
53.
go back to reference Lenci RE, Bevier M, Brandt A, Bermejo JL, Sucker A, Moll I, et al. Influence of genetic variants in type i interferon genes on melanoma survival and therapy. PLoS One. 2012;7(11):e50692.PubMedPubMedCentralCrossRef Lenci RE, Bevier M, Brandt A, Bermejo JL, Sucker A, Moll I, et al. Influence of genetic variants in type i interferon genes on melanoma survival and therapy. PLoS One. 2012;7(11):e50692.PubMedPubMedCentralCrossRef
54.
go back to reference Choi J, Song N, Han S, Chung S, Sung H, Lee JY, et al. The associations between immunity-related genes and breast cancer prognosis in Korean women. PLoS One. 2014;9(7):e103593.PubMedPubMedCentralCrossRef Choi J, Song N, Han S, Chung S, Sung H, Lee JY, et al. The associations between immunity-related genes and breast cancer prognosis in Korean women. PLoS One. 2014;9(7):e103593.PubMedPubMedCentralCrossRef
55.
go back to reference Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, Vymetalkova V, et al. Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PLoS One. 2014;9(10):e111061.PubMedPubMedCentralCrossRef Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, Vymetalkova V, et al. Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PLoS One. 2014;9(10):e111061.PubMedPubMedCentralCrossRef
57.
go back to reference Napravnik S, Poole C, Thomas JC, Eron JJ. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr. 2002;31(1):11–9.PubMedCrossRef Napravnik S, Poole C, Thomas JC, Eron JJ. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr. 2002;31(1):11–9.PubMedCrossRef
58.
go back to reference Rindler AE, Kusejko K, Kuster H, Neumann K, Leemann C, Zeeb M, et al. The interplay between replication capacity of HIV-1 and surrogate markers of disease. J Infect Dis. 2022;226(6):1057–68.PubMedCrossRef Rindler AE, Kusejko K, Kuster H, Neumann K, Leemann C, Zeeb M, et al. The interplay between replication capacity of HIV-1 and surrogate markers of disease. J Infect Dis. 2022;226(6):1057–68.PubMedCrossRef
59.
go back to reference Petersdorf N, Ross JM, Weiss HA, Barnabas RV, Wasserheit JN, Beguelin C, et al. Systematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergy. J Int AIDS Soc. 2016;19:1–8.CrossRef Petersdorf N, Ross JM, Weiss HA, Barnabas RV, Wasserheit JN, Beguelin C, et al. Systematic review and meta-analysis of hepatitis C virus infection and HIV viral load: new insights into epidemiologic synergy. J Int AIDS Soc. 2016;19:1–8.CrossRef
60.
go back to reference Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. Crit Care. 2019;23(1):1–10.CrossRef Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. Crit Care. 2019;23(1):1–10.CrossRef
61.
go back to reference McLaren PJ, Porreca I, Iaconis G, Mok HP, Mukhopadhyay S, Karakoc E, et al. Africa-specific human genetic variation near CHD1L associates with HIV-1 load. Nature. 2023;620(7976):1025–30.PubMedPubMedCentralCrossRef McLaren PJ, Porreca I, Iaconis G, Mok HP, Mukhopadhyay S, Karakoc E, et al. Africa-specific human genetic variation near CHD1L associates with HIV-1 load. Nature. 2023;620(7976):1025–30.PubMedPubMedCentralCrossRef
Metadata
Title
The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants
Authors
Sara Bohnstedt Mørup
Preston Leung
Cavan Reilly
Brad T. Sherman
Weizhong Chang
Maja Milojevic
Ana Milinkovic
Angelike Liappis
Line Borgwardt
Kathy Petoumenos
Roger Paredes
Shweta S. Mistry
Cameron R. MacPherson
Jens Lundgren
Marie Helleberg
Joanne Reekie
Daniel D. Murray
for the INSIGHT FIRST and START study groups
Publication date
01-12-2024
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2024
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-024-00610-x

Other articles of this Issue 1/2024

AIDS Research and Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.